Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7Q9 | ISIN: BE0974260896 | Ticker-Symbol: 1C0
Stuttgart
27.06.25 | 09:46
0,411 Euro
+13,22 % +0,048
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELYAD ONCOLOGY SA Chart 1 Jahr
5-Tage-Chart
CELYAD ONCOLOGY SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,3470,42819:03

Aktuelle News zur CELYAD ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCelyad Oncology SA: Celyad Oncology Announces Strategic Review211Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company" or "Celyad") today announced that it is conducting a comprehensive review of strategic alternatives....
► Artikel lesen
02.04.Celyad Oncology SA GAAP EPS of -€0.14, revenue of €0.2M1
02.04.Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights431Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2024, and provides a business update. Matt Kane...
► Artikel lesen
18.02.Celyad Oncology SA: Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform484Regulatory News: Celyad Oncology (Euronext: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), today announces the publication of the preclinical data of the non-gene edited allogeneic...
► Artikel lesen
CELYAD ONCOLOGY Aktie jetzt für 0€ handeln
07.10.24Celyad Oncology SA: Celyad Oncology to Present at the 2024 SITC Annual Meeting522Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held...
► Artikel lesen
16.09.24Celyad Oncology SA: Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer826Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") is pleased to announce Matt Kane as its new Chief Executive Officer (CEO), effective as of October 1st, 2024. Matt...
► Artikel lesen
13.09.24Celyad Oncology SA: Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights453The Company continues to bolster its intellectual property estate and to pursue options to monetize it The Company's two main research and development platforms have delivered proof-of-concept...
► Artikel lesen
7 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1